Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | TK1 | P04183 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TK2 | O00142 | 2/20 | 0.52 |
| ▸ | TYMP | P19971 | 5/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22335551 | 0.85 | ABCG2 (0.46) | LMNATSHRALBTK1PKM | |
| SCHEMBL20149854 | 0.85 | ABCG2 (0.46) | LMNATSHRALBTK1PKM | |
| SCHEMBL27508644 | 0.84 | LMNA (0.61) | LMNATSHRALBTK1PKM | |
| SCHEMBL9556674 | 0.82 | TK2 (0.57) | LMNAALBBLMTK2TYMP | |
| SCHEMBL20820141 | 0.82 | LMNA (0.61) | LMNATSHRALBTK1PKM | |
| SCHEMBL16081033 | 0.82 | LMNA (0.61) | LMNATSHRALBTK1PKM | |
| SCHEMBL18503453 | 0.81 | TK2 (0.59) | LMNAALBBLMTK2TYMP | |
| SCHEMBL7781617 | 0.81 | TK2 (0.61) | LMNAALBBLMTK2TYMP | |
| SCHEMBL17198387 | 0.79 | TK2 (0.55) | LMNAALBTK1BLMTK2 | |
| SCHEMBL13205001 | 0.77 | LMNA (0.59) | LMNATSHRALBTK1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210095284-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | Janssen Biopharma, Inc. | 2021-04-01 | — | — | US | disclosed |
| US-10793859-B2 | Modified oligonucleotides and methods of use | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | LMNA 808/4885TSHR 1957/4885ALB 2904/4885 |
| US-20210095284-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | MAPT, PSEN2, NSUN2 | LMNA 531/4885TSHR 3938/4885ALB 4221/4885 |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | LMNA 808/4885TSHR 1957/4885ALB 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.